RYA:EURONEXT DUBLINRyanair Holdings PLC Analysis
Data as of 2026-06-15 - not real-time
$8.56
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
RYA trades at $8.56, near its 20‑day SMA of 8.62 and just above the identified support of $7.82. The RSI sits at 46, indicating a market that is neither oversold nor overbought. MACD shows a bearish divergence with the histogram turning negative, suggesting short‑term downside pressure. Volume trend is decreasing, compounding the technical weakness. Volatility is elevated at roughly 49% over the past 30 days and beta exceeds 2, exposing the stock to amplified market swings. Fundamentally, the company posts a -9.5% revenue decline and operating margins deep in the negatives, while free cash flow remains negative.
However, debt is heavy – $763 million versus $68 million in cash, yielding a debt‑to‑equity ratio over 300%, which raises solvency concerns. The forward EPS of $1.09 translates to a forward P/E of about 7.9, and the price‑to‑book of 1.8 is well below peers, hinting at valuation headroom. The upside/downside estimate of +69% versus the current price suggests market participants see significant upside potential. The company’s diversified exposure across the US, Europe, and Asia mitigates some geographic concentration risk, but regulatory scrutiny in chemicals remains a factor. With no dividend and a negative ROE, income‑oriented investors have limited appeal. Overall, the stock sits at a crossroads where technical weakness clashes with a relatively attractive value proposition, making a cautious, staged approach prudent.
However, debt is heavy – $763 million versus $68 million in cash, yielding a debt‑to‑equity ratio over 300%, which raises solvency concerns. The forward EPS of $1.09 translates to a forward P/E of about 7.9, and the price‑to‑book of 1.8 is well below peers, hinting at valuation headroom. The upside/downside estimate of +69% versus the current price suggests market participants see significant upside potential. The company’s diversified exposure across the US, Europe, and Asia mitigates some geographic concentration risk, but regulatory scrutiny in chemicals remains a factor. With no dividend and a negative ROE, income‑oriented investors have limited appeal. Overall, the stock sits at a crossroads where technical weakness clashes with a relatively attractive value proposition, making a cautious, staged approach prudent.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD histogram
- Decreasing trading volume
- Proximity to technical support
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- High beta and volatility
- Heavy debt load
- Forward earnings visibility
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Attractive forward P/E and price‑to‑book
- Upside potential of ~70%
- Diversified global product exposure
Key Metrics & Analysis
Financial Health
Revenue Growth-9.50%
Profit Margin-32.82%
P/E Ratio7.9
ROE-100.54%
ROA-0.10%
Debt/Equity316.75
P/B Ratio1.8
Op. Cash Flow$16.2M
Free Cash Flow$-42060752
Technical Analysis
TrendNeutral
RSI46.6
Support$7.82
Resistance$9.34
MA 20$8.62
MA 50$9.18
MA 200$7.94
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Target Price$14.50
Upside/Downside69.39%
GradeUndervalued
TypeValue
Risk Assessment
Beta2.05
Volatility49.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.